Skip to main content
Home / News / Certara Recognized by NJBIZ as One of New Jersey’s Best Places to Work

Certara Recognized by NJBIZ as One of New Jersey’s Best Places to Work

Princeton, N.J., June 29, 2021: Certara, the global leader in biosimulation, today announced that it has been recognized as one of the “Best Places to Work” in New Jersey in 2021 by NJBIZ, one of New Jersey’s leading business journals. Certara is headquartered in Princeton, N.J.

“We are honored to be named one of the best places to work in New Jersey in a year where we continue to grow rapidly while dealing with the challenges of the COVID-19 pandemic,” said Certara’s CEO William Feehery, Ph.D. “As a mission-driven company, our people and culture of teamwork, innovation, and passion are critical to our success.  I would like to thank our dedicated team who is responsible for this distinction and contribute to our thriving work environment.”

Certara’s mission is to accelerate medicines to patients using biosimulation and technology.  The Certara team includes approximately 1,000 scientists and experts worldwide who transform drug development by partnering with biopharmaceutical companies, including the top 35 leading, global companies. 

NJBIZ’s survey and recognition program are dedicated to identifying and recognizing the best employers in the state. The NJBIZ honorees are decided based upon their participation with the Best Places to Work survey, from fellow BridgeTower Media firm Best Companies Group. The program confidentially collects data, allowing workers to comfortably share feedback about their employers, and for those companies to learn from and act on what they learn. Certara and the other winners’ rankings will be revealed at an upcoming award event on September 9, 2021. For additional information or to register for the event follow this link:

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:

David Deuchler
Gilmartin Group

Media Contact:

Ariane Lovell
Finn Partners